Medicare Enrolled
Dr. Mehdi Moezi, MD
Hematology & Oncology · Fleming Island, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Moezi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Moezi? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Moezi
Dr. Mehdi Moezi is a hematology & oncology in Fleming Island, FL, with 20 years in practice. Based on federal Medicare data, Dr. Moezi performed 101,772 Medicare services across 3,962 unique beneficiaries.
Between the years covered by Open Payments, Dr. Moezi received a total of $54,915 from 54 pharmaceutical and/or device companies across 286 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Moezi is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 7% volume in FL$ $54,915 industry payments
Medicare Practice Summary
Medicare Utilization ↗101,772
Medicare services
Top 7% in FL for hematology & oncology
3,962
Unique beneficiaries
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~5,089 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) | 42,750 | $1 | $4 |
| Contrast dye for imaging (iodine-based) | 36,500 | $0 | $1 |
| Denosumab injection (Prolia/Xgeva) | 5,580 | $18 | $39 |
| MRI contrast dye injection (gadoterate) | 3,214 | $0 | $25 |
| Epoetin alfa injection (Retacrit) for anemia | 3,000 | $6 | $27 |
| Blood draw (venipuncture) | 1,465 | $8 | $18 |
| Dexamethasone injection (steroid) | 1,404 | $0 | $1 |
| Complete blood count (CBC) with differential | 1,324 | $8 | $41 |
| Anti-nausea injection (Aloxi/palonosetron) | 750 | $1 | $75 |
| Office visit, established patient (20-29 min) | 609 | $64 | $104 |
| Injection, granisetron hydrochloride, 100 mcg | 500 | $0 | $41 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 358 | $21 | $90 |
| Administration of chemotherapy into vein, 1 hour or less | 326 | $95 | $355 |
| Drug injection, under skin or into muscle | 300 | $10 | $42 |
| Office visit, established patient (30-39 min) | 280 | $92 | $162 |
| Ct scan of chest with contrast | 277 | $54 | $500 |
| Urinalysis, manual | 223 | $3 | $15 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 222 | $397 | $1,000 |
| CT scan of chest, without contrast | 208 | $46 | $310 |
| CT scan of abdomen and pelvis with contrast | 207 | $165 | $535 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 204 | $1,090 | $2,400 |
| Injection, zoledronic acid, 1 mg | 163 | $6 | $282 |
| Blood creatinine level | 162 | $5 | $29 |
| Mri scan of brain before and after contrast | 157 | $121 | $571 |
| Administration of chemotherapy into vein, each additional hour | 157 | $21 | $80 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 136 | $46 | $160 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 136 | $71 | $70 |
| Ct scan of abdomen and pelvis without contrast | 111 | $73 | $270 |
| Injection, diphenhydramine hcl, up to 50 mg | 109 | $1 | $4 |
| Mri scan of abdomen before and after contrast | 102 | $132 | $663 |
| Injection of additional new drug or substance into vein | 82 | $12 | $55 |
| Administration of additional new drug or substance into vein, 1 hour or less | 71 | $49 | $175 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 71 | $1 | $7 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 64 | $25 | $84 |
| Collection of blood sample from implanted device | 48 | $19 | $45 |
| Infusion into a vein for hydration, each additional hour | 40 | $9 | $40 |
| New patient office visit (45-59 min) | 37 | $122 | $265 |
| Infusion, normal saline solution , 1000 cc | 37 | $2 | $97 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 36 | $14 | $55 |
| Mri scan of lower spinal canal before and after contrast | 35 | $105 | $579 |
| Stool analysis for blood to screen for colon tumors | 35 | $4 | $22 |
| Infusion into a vein for hydration, 31-60 minutes | 34 | $25 | $130 |
| Nuclear medicine study whole body with ct scan | 32 | $1,077 | $2,490 |
| Ct scan of soft tissue of neck with contrast | 27 | $63 | $495 |
| Irrigation of implanted venous access drug delivery device | 26 | $18 | $110 |
| Mri scan of pelvis before and after contrast | 24 | $134 | $650 |
| Initial hospital admission, moderate complexity | 24 | $103 | $225 |
| Hospital follow-up visit, moderate complexity | 22 | $63 | $115 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 19 | $1 | $21 |
| Low dose ct scan of chest for lung cancer screening | 17 | $83 | $213 |
| Ct scan of blood vessels of chest with contrast | 17 | $125 | $1,305 |
| Ct scan of soft tissue of neck without contrast | 16 | $44 | $315 |
| Ct scan of abdomen before and after contrast | 12 | $118 | $585 |
| Initial hospital admission, high complexity | 12 | $137 | $330 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
42.7% high complexity
52.7% medium
4.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$54,915
Total received (2018-2024)
Avg $7,845/year across 7 years
Top 13% in FL for hematology & oncology
54
Companies
286
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$33,039 (60.2%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$11,388 (20.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$10,488 (19.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$588
2023$369
2022$4,349
2021$2,683
2020$1,916
2019$17,827
2018$27,184
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Takeda Pharmaceuticals U.S.A., Inc.
$31,735
Genentech, Inc.
$6,908
E.R. Squibb & Sons, L.L.C.
$4,833
AbbVie, Inc.
$4,091
GlaxoSmithKline, LLC.
$2,876
PFIZER INC.
$660
Gilead Sciences, Inc.
$570
Novartis Pharmaceuticals Corporation
$434
Octapharma USA, Inc.
$280
Foundation Medicine, Inc.
$253
Janssen Biotech, Inc.
$224
Janssen Scientific Affairs, LLC
$163
Seagen Inc.
$160
Daiichi Sankyo Inc.
$157
Merck Sharp & Dohme Corporation
$154
Astellas Pharma US Inc
$111
Genentech USA, Inc.
$105
Eisai Inc.
$95
Regeneron Healthcare Solutions, Inc.
$89
SANOFI-AVENTIS U.S. LLC
$82
Alexion Pharmaceuticals, Inc.
$66
AstraZeneca Pharmaceuticals LP
$56
Kyowa Kirin, Inc.
$54
Celgene Corporation
$54
EMD Serono, Inc.
$51
EISAI INC.
$49
Incyte Corporation
$41
Aurobindo Pharma USA, Inc.
$40
TESARO, Inc.
$39
G1 Therapeutics, Inc.
$32
GENZYME CORPORATION
$31
MEDIVATION FIELD SOLUTIONS LLC
$30
AMAG Pharmaceuticals, Inc.
$28
JAZZ PHARMACEUTICALS INC.
$28
Merck Sharp & Dohme LLC
$27
Ipsen Biopharmaceuticals, Inc
$26
Sirtex Medical Inc
$22
ARRAY BIOPHARMA INC
$19
Amgen Inc.
$19
Secura Bio, Inc.
$19
TerSera Therapeutics LLC
$18
Tempus AI, Inc
$17
Boehringer Ingelheim Pharmaceuticals, Inc.
$16
Rigel Pharmaceuticals, Inc.
$16
Sun Pharmaceutical Industries Inc.
$16
SERVIER PHARMACEUTICALS LLC
$15
Exelixis Inc.
$15
Lexicon Pharmaceuticals, Inc.
$15
SOBI, INC
$14
Adaptive Biotechnologies Corporation
$13
Array BioPharma Inc.
$13
INSYS Therapeutics Inc
$12
Global Blood Therapeutics, Inc.
$12
Pharmacyclics LLC, An AbbVie Company
$11
Top 3 companies account for 79.2% of total payments
Associated products mentioned in payments ›
Alecensa · Avastin · BAVENCIO · BLENREP · BOSULIF · BRAFTOVI · Balversa · Bavencio · Braftovi · CABLIVI · CABOMETYX · COSELA · DARZALEX · ELIQUIS · ELREXFIO · EMEND · EMPLICITI · Enhertu · Erleada · FARESTON · FERAHEME · FOUNDATIONONE · Fabhalta · Farydak · Folotyn · GAUCHER-DISEASE · GAZYVA · GILOTRIF · Halaven · IBRANCE · IMBRUVICA · INJECTAFER · Imbruvica · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · LIBTAYO · LUTATHERA · Lenvima · Lunsumio · MEKINIST · MYLOTARG · NINLARO · Non-Covered Product · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OPDIVO · OPDUALAG · OXBRYTA · PADCEV · PLUVICTO · POTELIGEO · PROMACTA · Phesgo · REBLOZYL · ROZLYTREK · RYBREVANT · RYDAPT · Revlimid · Rezlidhia · SANCUSO · SCEMBLIX · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SUTENT · SYNDROS · TABRECTA · TASIGNA · Tibsovo · Trodelvy · ULTOMIRIS · Ultomiris · VENCLEXTA · VONJO · VOTRIENT · VYNDAQEL · Vectibix · Venclexta · WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · XALKORI · XOSPATA · XTANDI · Xermelo · Xtandi · YONSA · ZEJULA · ZEPZELCA · ZOLADEX · Zevalin · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (60%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Equivalent to $54 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
103
Per 100K population
46.1
County median income
$86,094
Nearest hospital
HCA FLORIDA ORANGE PARK HOSPITAL
5.3 mi
5.3 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Moezi is a mixed practice specialist, with above-average Medicare volume (top 7% in FL), and high industry engagement (consulting-driven, top 13%), with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Moezi experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Moezi performed 42,750 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Moezi receive payments from pharmaceutical companies?
Yes. Dr. Moezi received a total of $54,915 from 54 companies across 286 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Moezi's costs compare to other hematology & oncologys in Fleming Island?
Dr. Moezi's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Moezi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in Fleming Island
Browse hematology & oncologys in Fleming Island ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in FL
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in FL
Which FL hematology & oncologys receive the most from drug and device companies.
By company
Takeda Pharmaceuticals U.S.A., Inc. Payments to Doctors
See all physicians who received payments from Takeda Pharmaceuticals U.S.A., Inc..
By company
Genentech, Inc. Payments to Doctors
See all physicians who received payments from Genentech, Inc..
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology